Dermavant Sciences: Dermavant to Present Data from Multiple Clinical Trials of VTAMA (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference

- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical

Related Keywords

United States ,Las Vegas ,Nevada ,Americans ,Laurence Watts ,Christopherem Griffiths ,Mark Lebwohl ,Stephenc Piscitelli ,Philipm Brown ,Markg Lebwohl ,Aprilw Armstrong ,Bruce Strober ,Kima Papp ,Scott Guenthner ,Annam Tallman ,Robert Bissonnette ,Angela Salerno Robin ,Amy Paller ,Kostenloser Wertpapierhandel ,Davids Rubenstein ,Johne Jett ,Wynn Hotel In Las Vegas ,Twitter ,Drug Administration ,Dermavant Sciences Gmb ,National Prescription Audit ,Roivant Sciences ,Dermavant Sciences Inc ,Dermavant Sciences ,Linkedin Dermavant Sciences ,Clinical Dermatology Conference ,Wynn Hotel ,Tapinarof Cream ,Once Daily ,Extensive Atopic Dermatitis ,Week Maximal Use ,Plaque Psoriasis ,Pooled Efficacy ,Three Phase ,Linda Stein Gold ,Exposure Response Analysis Demonstrates ,Local Effects ,James Del Rosso ,Treat To Target Outcomes ,Treatment Success ,Severe Plaque ,Psoriasis Area Severity Index ,Clinical Efficacy ,Two Pivotal Phase ,Dermatology Life Quality Index ,Global Assessment ,Prescribing Information ,Patient Information ,Prescription Audit ,Vice President ,Media Relations ,Dermavant ,Ciences ,Present ,Data ,Rom ,Multiple ,Linical ,Trials ,Mtama ,Tapinarof ,Cream ,022 ,Wall ,Ermatology ,Conference ,